



10th International Conference on Thrombosis & Hemostasis Issues in Cancer


April 22—26. 2021

VIRTUAL EDITION

Program

icthic.com

The meeting is held under the auspices of:



Società Italiana di Ematologia (SIE)



Società Italiana per lo Studio dell'Emostasi e della Trombosi



Conference Chairmen

Anna Falanga, MD

Professor of Hematology,
University of Milano-Bicocca
Director Department of
Immunohematology and Transfusion
Medicine
Director Hemostasis and Thrombosis
Center
Hospital Papa Giovanni XXIII
Bergamo, Italy

Benjamin Brenner, MD

Professor of Hematology
Caster Chair of Leukemia Research
Director Department of Hematology
and Bone Marrow Transplantation
Director Thrombosis and Hemostasis
Unit
Rambam Health Care Campus
Technion, Israel Institute of Technology
Haifa, Israel

Alok A. Khorana, MD, FACP

Professor of Medicine, Cleveland Clinic
Lerner College of Medicine,
Case Western Reserve University
Sondra and Stephen Hardis Chair
in Oncology Research, Vice Chair
(Clinical Services), Director GI
Malignancies Program
Taussig Cancer Institute,
Cleveland Clinic
Cleveland, USA

Chairman Emeritus

Frederick R. Rickles, MD, FACP

Professor of Medicine, Pediatrics, Pharmacology and Physiology
The George Washington University, Katzen Cancer Center, Medical Faculty Associates, Washington D.C., USA
& Division of Hematology, Department of Medicine
Veterans Health Administration Medical Center, Washington D.C., USA

Organizing Committee

Anna Falanga
Bergamo, Italy

Laura Russo
Bergamo, Italy

Benjamin Brenner
Haifa, Israel

Paola Trucillo
Bergamo, Italy

Alok A. Khorana
Cleveland, USA

Scientific Secretariat

Anna Falanga Department of Immunohematology
and Transfusion Medicine
Marina Marchetti Hospital Papa Giovanni XXIII
Laura Russo Piazza OMS, 1 – 24127 Bergamo, Italy
Alfonso Vignoli

Organizing Secretariat

Servizi C.E.C. Srl Via G. Verdi, 18 - 24121 Bergamo, Italy
Phone +39.035.249899 - Fax +39.035.237852
info@ictic.com

PROGRAM OVERVIEW

PROGRAM OVERVIEW





Thursday
April 22nd

Friday
April 23rd

Saturday
April 24th

Sunday
April 25th

Monday
April 26th



Virtual Room Legend

Aula Magna

- Congress opening
- Special session
Special lecture
6th Simon Karpatkin Memorial Lecture
- Plenary session 1-6
- Roundtables
- Debates
- Concluding Remarks

Room 5

- Satellite Symposia
- Poster discussion

FACULTY

Matti Aapro - Switzerland	Agnes Y.Y. Lee - Canada
Walter Ageno - Italy	Marcel M. Levi - The Netherlands
Giancarlo Agnelli - Italy	Howard A. Liebman - USA
Pantep Angchaisuksiri - Thailand	Gary H. Lyman - USA
Cihan Ay - Austria	Nigel Mackman - USA
Laurent Bertoletti - France	Mario Mandalà - Italy
Benjamin Brenner - Israel	Antony Maraveyas - UK
Marina Camera - Italy	Marina Marchetti - Italy
Suzanne C. Cannegieter - The Netherlands	Saskia Middeldorp - The Netherlands
Marc Carrier - Canada	Andrés J. Muñoz Martin - Spain
Elisabetta Castoldi - The Netherlands	Yona Nadir - Israel
Marco Cattaneo - Italy	Simon Noble - UK
Jean M. Connors - USA	Anne-Karin Olsson - Sweden
Erica De Candia - Italy	Ingrid Pabinger - Austria
Marcello Di Nisio - Italy	Joseph S. Palumbo - USA
Maria Benedetta Donati - Italy	José A. Páramo - Spain
Christophe Dubois - France	Paolo Prandoni - Italy
Ismail Elalamy - France	Janusz Rak - Canada
Elena Faioni - Italy	Andrea Remuzzi - Italy
Anna Falanga - Italy	Frederick R. Rickles - USA
Dominique Farge - France	Caterina Rizzi - Italy
Augusto B. Federici - Italy	Francesco Rodeghiero - Italy
Charles W. Francis - USA	Wolfram Ruf - Germany
Grigoris T. Gerotziakas - France	Per Morten Sandset - Norway
Raffaella Giavazzi - Italy	Kristen Sanfilippo - USA
Paolo Gresele - Italy	Miguel A. Sanz - Spain
Luis Jara-Palomares - Spain	Rita Selby - Canada
Karin Jordan - Germany	Sergio Mario Siragusa - Italy
Ajay J. Kakkar - UK	David M. Smadja - France
Gili Kenet - Israel	Gerald A. Soff - USA
Nigel Key - USA	Arina J. ten Cate - The Netherlands
Alok A. Khorana - USA	Hugo ten Cate - The Netherlands
Cliona Kirwan - UK	Nick Van Es - The Netherlands
Frederikus A. Klok - The Netherlands	Henri H. Versteeg - The Netherlands
Nicole Kuderer - USA	Annie Young - UK
Roberto Labianca - Italy	Sacha Zeerleder - Switzerland
Avi Leader - Israel	Jeffrey I. Zwicker - USA

PROGRAM

NOT CME ACCREDITED

Thursday 22nd

Aula Magna

15:00 – 15:15	Congress Opening Opening remarks from the Conference Chairmen A. Falanga, B. Brenner, A.A. Khorana	
15:15 – 16:30	Special Session COVID-19, cancer and thrombosis Chairs: P. Gresele (Italy), A. Falanga (Italy)	
	COVID-19 associated thrombosis - A year later J.M. Connors (USA)	L-01
	COVID-19 is an acquired vascular hemopathy D.M. Smadja (France)	L-02
	Selected Abstracts	
	Venous thromboembolic events during the first and second wave of Covid-19 in breast cancer patients treated in an outpatient day hospital J. Illarramendi, J.L. Modesto, E. Salgado, S. De la Cruz, J.J. Illarramendi (Spain)	OC-01
	Khorana risk score at diagnosis of SARS-CoV-2 infection as a predicting tool for venous thromboembolic disease development, and overall mortality, in cancer patients C. López Jiménez, C. Blanco Abad, J.L. Catoya Villa, A. Gutiérrez Ortiz de la Tabla, D.S. Juliao Caamaño, L. Ortega Morán, M. Martín Jiménez, A.J. Muñoz Martin (Spain)	OC-02
	Heparin treatment in COVID-19 patients is associated with reduced in-hospital mortality: findings from an observational multicenter study in Italy and a meta-analysis of 11 studies S. Costanzo, R. Parisi, G. de Gaetano, <u>M.B. Donati</u> , L. Iacoviello, A. Di Castelnuovo, on behalf of the COVID-19 RISK and Treatments (CORIST) collaboration (Italy)	OC-03

16:30 – 17:00

Special Lecture

Chair: A. Falanga (Italy)

Introduction to Lecture

C. Rizzi (Italy)

**Are the new technologies
useful to medicine or the opposite?**

A. Remuzzi (Italy)

17:15-18:15

Satellite symposium (see page 42)

◇ Room 5

Friday 23rd

Aula Magna

15:00 – 15:30

Plenary Lecture

6th Simon Karpatkin Memorial Lecture

Chairs: A. Falanga (Italy), B. Brenner (Israel), A.A. Khorana (USA)

Introduction to Lecture

F.R. Rickles (USA)

**Risk prediction for cancer-associated thrombosis in
ambulatory patients with cancer: past, present and
future**

I. Pabinger (Austria)

15:30 – 17:00

Plenary Session 1

**New insights in prevalence
of cancer-associated thrombosis**

Chairs: H.A. Liebman (USA), M. Aapro (Switzerland)

Screening for occult cancer: where are we in 2020?

L. Jara-Palomares (Spain)

PL-01

**An overview of thrombotic complications of old and
new anti-cancer drugs**

M.M. Levi (The Netherlands)

PL-02

Impact of arterial thrombosis in cancer patients

S.C. Cannegieter (The Netherlands)

PL-03

Cancer associated thrombosis in pediatric setting

G. Kenet (Israel)

PL-04

Selected Abstracts

**Incidence, predictors and clinical outcomes of venous
thromboembolism in patients with newly diagnosed
pancreatic ductal adenocarcinoma: results of the
prospective BACAP-VTE study**

C. Frere, B. Bournet, S. Gourgou, J. Fraisse, C. Canivet, J.M. Connors,
L. Buscail, D. Farge, on behalf of the Groupe Francophone
Thrombose et Cancer and the BACAP Consortium (France, USA,
Canada)

OC-04

Risk of venous thromboembolism in cancer patients: a cohort study
 F. Mulder, E. Horváth-Puhó, N. van Es, H.W.M. van Laarhoven, L. Pedersen, H.R. Büller, H.T. Sørensen (The Netherlands, Denmark)

OC-05

17:00 – 17:30

Roundtable

Risk assessment models for VTE in cancer
 Chairs: P. Angchaisuksiri (Thailand), C. Ay (Austria)

Introduction: overview of risk assessment models for VTE in ambulatory patients with cancer
 G.T. Gerotziakas (France)

Discussants: N. Van Es (The Netherlands), A. Falanga (Italy), A.A. Khorana (USA), G.T. Gerotziakas (France), M.B. Donati (Italy)

Saturday 24th

Aula Magna

11:00 – 11:30

Poster Session 1 (pages 20-21)

Prevention of thrombosis
 Chair: L. Bertolotti (France)
 ♡ Room 5

11:45 – 12:15

Poster Session 2 (pages 21-22)

Epidemiology I
 Chair: E. Faioni (Italy)
 ♡ Room 5

12:30 – 13:00

Poster Session 3 (pages 22-24)

Hypercoagulability in cancer
 Chair: C.C. Kirwan (UK)
 ♡ Room 5

14:00-15:00

Satellite symposium (see page 42)

♡ Room 5

15:00 – 16:30

Plenary session 2

Hematological malignancies
 Chairs: H. ten Cate (The Netherlands), F. Rodeghiero (Italy)

Risk-assessment of thrombosis and bleeding in hematological malignancies
 B. Brenner (Israel) *PL-05*

Advances in management of coagulopathy in APL
 M.A. Sanz (Spain) *PL-06*

Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia
 A. Leader (Israel) *PL-07*

Multiple myeloma-associated VTE risk prediction
 K. Sanfilippo (USA) *PL-08*

Selected Abstracts**The molecular mechanisms of ponatinib-induced thrombosis**

A.H. Schmaier, A.A. Merkulova, E.R. Chan, E.X. Stavrou, S.C. Mitchell, G.L. Forbes, P. Zeng (USA)

OC-06

Differences in thromboprophylaxis between hospitalized patients with solid or hematological malignancies

R. Figueroa, M. Marcos-Jubilar, A. García-Mouriz, J.A. Páramo, R. Lecumberri (Spain)

OC-07

16:30 – 17:00

Roundtable**Emerging practical guidelines for the prevention and treatment of CAT**

Chairs: M. Cattaneo (Italy), R. Labianca (Italy)

Introduction: overview of VTE treatment and prevention in cancer according to clinical guidelines

G.H. Lyman (USA)

Discussant: A. Falanga (Italy), A.Y.Y. Lee (Canada), D. Farge (France), K. Jordan (Germany), I. Elalamy (France), G.H. Lyman (USA)

17:00 – 18:45

Plenary Session 3**Biomarkers in CAT and cancer progression**

Chairs: N. Mackman (USA), A.K. Olsson (Sweden)

Impact of preclinical variables on thrombotic biomarkers levels in cancer

R. Selby (Canada)

PL-09

Biomarkers in cancer VTE: data from the AVERT study

N. Key (USA)

PL-10

Thrombotic biomarkers in occult cancer and cancer risk prediction

M. Marchetti (Italy)

PL-11

Genes and proteins associated with CAT risk

H.H. Versteeg (The Netherlands)

PL-12

Role of NETs in cancer associated-thrombosis

S. Zeerleder (Switzerland)

PL-13

Selected Abstracts**Biomarkers of venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis (HISPALIS - Study)**

R. Otero Candelera, V. Sánchez López, E. Arellano Orden, J. Oto Martinez, A. Solier-López, S. Marín Romero, L. Jara Palomares, T. Elías Hernández, M.I. Asencio Cruz, I. Blasco-Esquívias, M. Rodríguez de la Borbolla, J.M. Sánchez Díaz, F.J. Rodríguez Martorell, P. Medina Badenes (Spain)

OC-08

Proteomic profiling in cancer-associated VTE

M. Panova-Noeva, A. Schulz, T. Köck, V. ten Cate, B. Wagner, S. Rapp, M. Lenz, A. Zink, M. Ghadessi, S. Konstantinides, H. ten Cate, S. Heitmeier, P. Wild (Germany, The Netherlands)

OC-09

Sunday 25th

Aula Magna

- 11:00 – 11:30 **Poster Session 4** (pages 25-26)
Treatment of thrombosis
 Chair: A. Young (UK)
 ♡ Room 5
- 11:45 – 12:15 **Poster Session 5** (pages 26-27)
Epidemiology II
 Chair: A.B. Federici (Italy)
 ♡ Room 5
- 12:30 – 13:00 **Poster Session 6** (pages 27-28)
Therapeutic challenges
 Chair: M. Mandalà (Italy)
 ♡ Room 5
- 13:15 – 13:45 **Poster Session 7** (pages 29-30)
Hemostatic system/tumor biology interactions
 Chair: M. Camera (Italy)
 ♡ Room 5
- 15:00 – 16:45 **Plenary Session 4**
Bench to bedside: new insights into hemostasis and cancer
 Chairs: P.M. Sandset (Norway), R. Giavazzi (Italy)
- Genetic and epigenetic regulation of cancer coagulome - Lessons from heterogeneity of cancer cell populations** *PL-14*
 J. Rak (Canada)
- Coagulation signaling and cancer immuno-therapy** *PL-15*
 W. Ruf (Germany)
- Heparanase-revisited** *PL-16*
 Y. Nadir (Israel)

Mouse model of thrombosis and cancer *PL-17*
 C. Dubois (France)

The thrombin-inflammation axis in cancer progression *PL-18*
 J.S. Palumbo (USA)

Selected Abstracts

Thrombin tips the scales towards effective immune checkpoint blockade in cancer *OC-10*
 R. Cantrell, L. Rosenfeldt, D. Mureb, M. Lehn, B.K. Sharma, A. Revenko, B. Monia, E. Janssen, J.S. Palumbo (USA)

Plasminogen activator inhibitor 1 and venous thrombosis in nude mice bearing human pancreatic tumors *OC-11*
 Y. Hisada, A. Maqsood, K. B. Garratt, B. C. Cooley, N. Mackman (USA)

16:45 – 17:15 **Debate**
Outpatient prophylaxis: are we there yet?
 Chairs: G. Agnelli (Italy), C.W. Francis (USA)

NO: F.A. Klok (The Netherlands)

YES: A.A. Khorana (USA)

17:15 – 18:30 **Plenary Session 5**
Prevention of VTE in cancer patients
 Chairs: P. Prandoni (Italy), J.A. Paramo (Spain)

Inpatient thromboprophylaxis in cancer patients: what is the evidence? *PL-19*
 J.I. Zwicker (USA)

Roles of LMWH for prevention in cancer patients *PL-20*
 A. Maraveyas (UK)

Meta-analysis and systematic review of NOAC prophylaxis in high risk cancer outpatients *PL-21*
 N. Kuderer (USA)

Selected Abstracts

D-dimer levels significantly decline in ambulatory cancer patients receiving rivaroxaban compared to placebo: biomarker analysis of the CASSINI trial
 S. Vadhan-Raj, N. Kuderer, T. Wun, J. Patel, K. McCrae, X. Zhou, U. Vijapurkar, C.V. Damaraju, P. Wildgoose, G.H. Lyman, A.A. Khorana (USA)

OC-12

A clinical-genetic risk score to predict cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts
 A.J. Muñoz Martín, C. Ay, E. Grilz, S. López, C. Font, V. Pachón, V. Castellón, V. Martínez-Marín, M. Salgado, E. Martínez, J. Calzas, A. Rupérez, E. Salas, I. Pabinger, J.M. Soria (Spain, Austria)

OC-13

Monday 26th

Aula Magna

11:00 – 11:30

Poster Session 8 (pages 31-32)

Thrombotic risk assessment
 Chair: A.J. Ten Cate (The Netherlands)

◇ Room 5

11:45 – 12:15

Poster Session 9 (page 33)

Bleeding complications
 Chair: E. De Candia (Italy)

◇ Room 5

12:30 – 13:00

Poster Session 10 (pages 34-35)

New experimental and clinical approaches
 Chair: E. Castoldi (The Netherlands)

◇ Room 5

15:00 – 16:40

Plenary Session 6

Evolving Data for Treatment of VTE in cancer
 Chairs: G. Soff (USA), W. Ageno (Italy)

Anticoagulation in Cancer Patients: advantages and disadvantages

A.J. Munoz (Spain)

PL-22

VTE management:

emerging insights from the GARFIELD VTE registry
 A.J. Kakkar (UK)

PL-23

Treatment of VTE in cancer patients: from clinical trials to real life

G. Agnelli (Italy)

PL-24

VTE in palliative care patients: what do we know?
 S. Noble (UK)

PL-25

Selected Abstracts

Risk factors for recurrence in patients with cancer-associated venous thromboembolism: results from the Hokusai-VTE cancer study

E.T.M. Bosch, T.F. Wang, M. Di Nisio, A. Segers, J.M. Connors, D. Garcia, F.I. Mulder^{1,2}, J. Weitz, H.R. Büller, M. Carrier, P. Verhamme, M. Grosso, G. Raskob, N. van Es (The Netherlands, USA)

Risk factors of recurrence in cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a RIETE-based prospective study

E.X. Lapébie, A. Bura-Rivière, A. Merah, L. Bertoletti, M. Monreal, RIETE investigators (France, Spain)

Apixaban as treatment for cancer-associated venous thrombosis - The CAP study

T.L. Hannevik, J. Brekke, T. Enden, H. Frøen, H. Garresori, W. Ghanima, E.M. Jacobsen, P.Q. Paulsen, A.C. Porojnicu, A.H. Ree, P.M. Sandset, D. Torfoss, E.O. Velle, H.S. Wik, A.E.A. Dahm (Norway)

Rivaroxaban versus dalteparin for the treatment of cancer-associated venous thromboembolism: the CASTA DIVA Trial

G. Meyer, P. Girard, L. Bertoletti, A.C. Nelson, S. Laporte, I. Mahé, O. Sanchez, P. Mismetti, on behalf the CASTA DIVA Investigators (France)

OC-14

OC-15

OC-16

OC-17

16:40 – 17:10

Debate

Incidental VTE: to treat or not to treat?

Chairs: S. Siragusa (Italy), S. Middeldorp (The Netherlands)

YES: M. Di Nisio (Italy)

NO: M. Carrier (Canada)

17:10 – 17:15

Concluding Remarks

A. Falanga, B. Brenner, A.A. Khorana

17:15-18:15

Satellite symposium (see page 43)

◇ Room 5

Saturday 24th

11.00 – 11.30

Poster Session 1

Prevention of thrombosis

Chair: L. Bertoletti (France)

- PO-01 Rivaroxaban (RX) for the prevention of venous thromboembolism (VTE) in cancer patients (CP) receiving chemotherapy (CHT)**
V.A. Sukhanov, O.Y. Petrova
- PO-02 Using the CAT Score to improve thromboprophylaxis in ambulatory cancer patients**
V. Kumar, N.S. Key, A. Ilich, J. Shaw, R. Mallick, P. Wells, M. Carrier
- PO-03 Is extended thromboprophylaxis required for all gynaecological cancer patients post-surgery?**
F. Abu Saadeh, Z. Marchocki, S.A. O'Toole, N. Gleeson, A. Kashan, L.A. Norris
- PO-04 The impact of a patient information video on patient awareness and understanding of chemotherapy induced cancer associated thrombosis**
E. Baddeley, N. Pease, A. Nelson, J. Sulma, A. Crabtree, S. Noble
- PO-05 High rates of venous and arterial thrombotic events in POEMS patients: results from the UCLH POEMS registry (UK), highlighting the need for therapeutic guidelines**
Z. Sayar, A. Weatherill, S. Keddie, J. Sive, M.P. Lunn, M. Thomas, S. D'Sa
- PO-06 A novel approach to venous thromboembolism thromboprophylaxis in multiple myeloma: a single-centre approach**
Z. Sayar, C. Gates, M. Thomas
- PO-07 Comparison of primary thromboprophylaxis agents (PTA) efficacy in multiple myeloma (MM) treated with immunomodulators (IMiD): a network meta-analysis**
P. Haddad, K. Gallagher, D. Hammoud

- PO-08 Cancer outpatients under thromboprophylaxis: an analysis of choices and events**
J. Liz Pimenta, K. Ladeira, A. Teira, M. Rocha, P. Gago, D. Azevedo, E. Cadavez, P. Liu, S. Duarte, I. Grilo, R. Gomes, T. Sarmento, M. Sousa, M. Castelo Branco, M. Barbosa
- PO-09 Very high-risk patients: a prospective study of thromboembolic events in patients under thromboprophylaxis**
J. Liz Pimenta, K. Ladeira, A. Teira, M. Rocha, P. Gago, D. Azevedo, E. Cadavez, P. Liu, S. Duarte, I. Grilo, T. Sarmento, M. Sousa, M. Castelo Branco, R. Gomes, M. Barbosa

11.45 – 12.15

Poster Session 2

Epidemiology I

Chair: E. Faioni (Italy)

- PO-10 Epidemiology of venous thromboembolism after development of second cancer**
I.L. Gade, M.T. Severinsen, K.K. Kragholm, S.R. Kristensen, C. Torp-Pedersen, S.J. Riddersholm
- PO-11 Venous thromboembolism in ovarian cancer patients: a nationwide Danish cohort study**
H.S. Kahr, O.B. Christiansen, S.J. Riddersholm, I.L. Gade, C. Torp-Pedersen, A. Knudsen, O. Thorlacius-Ussing
- PO-12 Venous thromboembolism and risk of cancer in users of statins: a Danish population-based cohort study**
N. Skajaa, D. Nagy, F.S. Troelsen, D.K. Farkas, H.T. Sørensen
- PO-13 Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study (STAC)**
M.J.T. Crobach, R.J.S. Anijs, S.K. Brækkan, M.T. Severinsen, J. Hammerstrøm, H. Skille, S.R. Kristense, B. Paulsen, A. Tjønneland, H.H. Versteeg, K. Overvad, J. Hansen, I.A. Næssk, S.C. Cannegieter
- PO-14 Venous thromboembolism and risk of cancer in women treated with postmenopausal hormone replacement**
L.S. Svingel, D. Nagy, F.S. Troelsen, D.K. Farkas, H.T. Sørensen

- PO-15 Venous thromboembolism may be a marker of occult cancer in patients with kidney disease**
A.D. Kjaergaard, D. Nagy, C.F. Christiansen, F.S. Troelsen, D.K. Farkas, H.T. Sørensen
- PO-16 Venous thromboembolism in small cell lung cancer patients: an epidemiological study**
E. Dimakakos, K. Livanios, E. Kainis, A. Vassias, D. Stefanou, E. Kotteas, G.T. Gerotziakas, K. Syrigos
- PO-17 Mesothelioma: a retrospective study of thromboembolism events**
E. Dimakakos, K. Basdeki, I. Gkiozos, S. Tsagkouli, N. Rovina, P. Mpakakos, N. Ptohis, I. Trontzas, E. Kotteas, K. Syrigos
- PO-18 Venous thromboembolism and risk of cancer in patients with dementia: a Danish population-based cohort study**
C.H. Fuglsang, D. Nagy, F.S. Troelsen, D.K. Farkas, V.W. Henderson, H.T. Sørensen
- PO-19 Initiation of low-dose aspirin and risk of colorectal neoplasms: a population-based matched cohort study in Denmark**
E. Schønfeldt Troelsen, D. Körmendiné Farkas, R. Erichsen, H.T. Sørensen
- PO-20 Incidence of venous thromboembolism in men with prostate cancer and men without prostate cancer: a nationwide population-based cohort study in Sweden**
B. Farahmand, Y. Balabanova, P. Stattin, H. Garmo, G. Brobert
- PO-21 Incidence of venous thromboembolism events in outpatients with cancer and COVID-19**
A. Gutiérrez Ortiz de la Tabla, D.S. Juliao Caamaño, C. López Jiménez, C. Blanco Abad, J.L. Catoya Villa, L. Ortega Morán, M. Martín, A.J. Muñoz Martín
- PO-22 Venous thromboembolism in cancer patients – data from Regional Centre for transfusion medicine Shtip**
M. Shorova

12.30 – 13.00

Poster Session 3

Hypercoagulability in cancer

Chair: C.C. Kirwan (UK)

- PO-23 Hypercoagulability in upper gastrointestinal cancer patients: a longitudinal study**
A.C. Larsen, J. Brøndum Frøkjær, R.V. Fisker, M. Yilmaz, S.R. Kristensen, O. Thorlacius-Ussing

- PO-24 Lung cancer: the clinical profile of D-dimers**
E. Kokkotou, I. Gkiozos, D. Vassos, S. Karakatsanis, E. Kotteas, G.T. Gerotziakas, K. Syrigos, E. Dimakakos
- PO-25 Plasma levels of activated factor VII–antithrombin complex predict mortality in subjects with liver and colon cancer undergoing curative surgical intervention**
N. Martinelli, S. Moruzzi, A. Castagna, S. Udali, M. Baroni, P. Pattini, A. Ruzzenente, S. Conci, T. Campagnaro, B. Woodhams, P. Van Dreden, A. Guglielmi, F. Bernardi, O. Olivieri, S. Friso
- PO-26 Fibrinogen levels and risk of colorectal cancer in a case-cohort study from the Italian general adult population: results from the Moli-sani study**
S. Costanzo, A. De Curtis, A. Di Castelnuovo, T. Panzera, M. Persichillo, A. Falanga, S. Gamba, L. Russo, M. Marchetti, G. de Gaetano, M.B. Donati, L. Iacoviello, on behalf of the Moli-sani Study Investigators
- PO-27 Tissue plasminogen activator and risk of breast cancer in a case-cohort study from Italian women of a general population: results from the Moli-sani study**
S. Costanzo, A. De Curtis, A. Di Castelnuovo, T. Panzera, M. Persichillo, A. Falanga, S. Gamba, L. Russo, M. Marchetti, G. de Gaetano, M.B. Donati, L. Iacoviello, on behalf of the Moli-sani Study Investigators
- PO-28 Circulating markers of neutrophil activation and nets, but not of coagulation and fibrinolysis, predict mortality in patients with terminal cancer**
A. Rosell, K. Aguilera, M. Daleskog, Y. Hisada, N. Mackman, S. Lundström, H. Wallén, C. Thålin
- PO-29 Plasma levels of procoagulant and anticoagulant factors in patients with acute cancer-associated thrombosis**
E. Campello, L. Spiezia, C. Simion, E. Rosin, C. Bulato, C.M. Radu, M. Fadin, S. Gavasso, P. Simioni
- PO-30 Inherited deficiency of antithrombin, protein C or protein S is associated with an increased risk of cancer at a younger age**
D. Tormene, S. Gavasso, G. Turatti, C. Simion, M. Marobin, E. Campello, P. Simioni
- PO-31 Changes in ADAMTS13 and vWF activity as a potential predictor of thrombotic complications in women with ovarian cancer undergoing chemotherapy**
A.V. Vorobyev, M. Meng, V.O. Bitsadze, D.Kh. Khizroeva, A.G. Solopova, A.D. Makatsariya
- PO-32 Integral laboratory hemostasis tests in diagnosis of hypercoagulation and assessment of thrombosis risk in patients with brain glioma**
I.A. Vasilenko, D.V. Mosalskaya, A.N. Khmelevskaya, A.S. Balkanov, V.B. Metelin
- PO-33 Hemostatic activation and fibrinolysis with prostate cancer before and after hormonal therapy**
J. Nauseef, M. Sun, C. Thomas, Y. Zakharia, P. Christos, D.M. Nanus, S.T. Tagawa

- PO-34** A case of normal range D-dimer levels in a patient with deep vein thrombosis and active cancer
V. Muster, K. Gütl, L. Schweiger, P. Gressenberger, R.B. Raggam, M. Brodmann, T. Gary
- PO-35** Analysis of coagulation parameters in patients with COVID-19, data from Regional Center Shtip
M. Shorova

Sunday April 25th

11.00 – 11.30

Poster Session 4

Treatment of thrombosis

Chair: A. Young (UK)

- PO-36** Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomisation of the SELECT-D trial
A. Marshall, A.M. Young, M. Levine, C. Hill, D. Hale, J. Thirlwall, V. Wilkie, K. French, A.K. Kakkar, A. Lokare, A. Maraveyas, O. Chapman, A. Arif, S. Petrou, M. Maredza, F.D.R. Hobbs, J.A. Dunn, on behalf of the SELECT-D Collaborative Group
- PO-37** How are patients with active cancer and venous thromboembolism (VTE) treated in Germany? Answers from GECAT (German Evaluation of Cancer Associated Thrombosis)
M. Sinn, C. Pollich, H. Riess, S. Bischoff, P. Habbel, C.W. Scholz, E. Spaeth-Schwalbe, M. de Wit, A. Jühling, E. Wolter, L. Wislocka, R. Klamroth
- PO-38** Management of cancer associated thrombosis in Denmark: findings from a nationwide survey
A.A. Højen, M. Nybo, T. Kümler, M.S. Rasmussen, T.D. Christensen, T.B. Larsen
- PO-39** Superficial venous thrombosis in patients with active cancer: characteristics and management
L. Ghenassia-Fouillet, A. Morel, P. Frappé, C. Le Hello, V. Lerche, M.-A. Sevestre, L. Bertoletti
- PO-40** Educational and financial impact of a recommendation on cancer-associated thrombosis (CAT) management: experience of a Brazilian oncological Public Hospital for adults
C. Rothschild, M.P.E. Diz, A.E. Zerati, A.H. Sabanai, G.M. Albuquerque, T.T. Takahashi, A.A.G.S. Brandão, J. Pereira, V. Rocha
- PO-41** Paraneoplastic deep vein thrombosis in pre-existing full-dose anticoagulation with dabigatran: a case report
K. Guetl, V. Muster, P. Gressenberger, R.B. Raggam, M. Brodmann, T. Gary
- PO-42** Unprovoked thrombosis: when cancer associated thrombosis could be the first diagnosis – A case report
A.B. Vilaseca, M.B. Romero, S.L. Battiston

VIRTUAL POSTER SESSIONS

Room 5

- PO-43 A unique approach to anticoagulation in a morbidly obese patient with endometrial cancer and venous thromboembolism**
M.T. Tso, O.M. Moodley, H. Chalchal
- PO-44 Health care resource utilization and costs associated with venous thromboembolism recurrence in cancer patients: SELECT-D trial**
M. Maredza, S. Petrou, A. Marshall, A.M. Young, on behalf of the SELECT-D Collaborative Group
- PO-45 Long-term anticoagulation for the treatment and secondary prophylaxis of venous thromboembolism among men with prostate cancer in Sweden: risk of recurrent venous thromboembolism and major bleeding**
G. Brobert, B. Farahmand, P. Stattin, H. Garmo, Y. Balabanova

11.45 – 12.15

Poster Session 5

Epidemiology II

Chair: A.B. Federici (Italy)

- PO-46 Cardiovascular disease events within 5 years after a diagnosis of breast cancer**
B. Mery, J. Catella-Chatron, A. Fouilloux, E. Rowinski, J.B. Guichard, A. Da Costa, F. Tinquaut, N. Magné, L. Bertoletti
- PO-47 Venous thromboembolism and risk of cancer in patients with diverticular disease: a Danish population-based cohort study**
E. Schønfeldt Troelsen, D. Nagy, N. Skajaa, D. Körmendiné Farkas, R. Erichsen, H.T. Sørensen
- PO-48 The risks of chemotherapy induced cancer associated thrombosis: what do patients know and what do they need to know?**
E. Baddeley, N. Pease, A. Nelson, J. Sulman, A. Crabtree, S. Noble
- PO-49 CNS thrombosis as initial symptom of ALK+ALCL in a child**
M. Karametou, V. Doulioglou, E. Pavlidou, I. Patoulas, P. Prassopoulos, T. Koletsa, M. Ioannidou, M. Palabougiouki, A. Tragiannidis, D. Sfougaris, T. Papageorgiou, E. Pavlou, E. Hatzipantelis
- PO-50 The role of the blood factors in the survival of patients with non-small cell lung cancer**
E. Dimakakos, K. Cholidou, P. Mpakakos, N. Anagnostopoulos, I. Gkiozos, N. Syrigos, E. Kotteas, G.T. Gerotziakas

VIRTUAL POSTER SESSIONS

Room 5

- PO-51 Saddle pulmonary embolism in the era of incidental events: incidence, clinical findings and outcomes in a single-center cohort**
M. Aramberri, C. Diaz-Pedroche, M. Benegas, M. Sanchez, F. Esposito, A. Rodriguez-Hernandez, E. Seguí, A. García-Villa, C. Font
- PO-52 Immunophenotypic analysis of haematological malignancies in a Pakistani population: a step towards formulation of hospital cancer registry**
A.M. Memon, N.A. Ali, A. Ahmed
- PO-53 Risk of cancer in patients with psoriasis and venous thromboembolism: a Danish population-based cohort study 1996 – 2017**
S.T. Sørensen, D. Nagy, L.M. Lindahl, D.K. Farkas, E.S. Troelsen
- PO-54 Venous thromboembolism and risk of cancer in users of low-dose aspirin: a Danish population-based cohort study**
F. Schønfeldt Troelsen, D. Nagy, N. Skajaa, D. Körmendiné Farkas, R. Erichsen, H.T. Sørensen
- PO-55 Outcomes and a predictive model for survival in postoperative endometrial cancer patients with venous thromboembolism**
J. Easaw, J. Mateshaytis, S. Ghosh, E. Batuyong, S. Pin
- PO-56 Relationship between clinical presentation of SARS-CoV-2 infection and risk of thromboembolic events and prognosis in cancer patients**
J.L. Catoya Villa, A. Gutiérrez Ortiz de la Tabla, D.S. Julio Caamaño, C. López Jiménez, C. Blanco Abad, L. Ortega Morán, M. Martín Jiménez, A.J. Muñoz Martín
- PO-57 Characteristics of venous thromboembolism following COVID-19 in Croatia**
B. Barišić, S. Zupančić-Šalek, D. Županić Krmek, M. Međugorac, E. Galić, J. Faletar
- PO-58 Venous and arterial thromboembolic events among hospitalized cancer patients with SARS-COV2 infection**
C. Blanco Abad, J.L. Catoya Villa, A. Gutiérrez Ortiz de la Tabla, D.S. Julio Caamaño, C. López Jiménez, L. Ortega Morán, M. Martín Jiménez, A.J. Muñoz Martín

12.30 – 13.00

Poster Session 6

Therapeutic challenges

Chair: M. Mandalà (Italy)

- PO-59 Anticoagulant therapy as a potential intervention to prevent relapse in patients with advanced ovarian cancer**
A.V. Vorobyev, S.S. Petrova, V.S. Sannikova, M. Meng, V.O. Bitsadze, D.Kh. Khizroeva, A.G. Solopova, A.D. Makatsariya

- PO-60 Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune check-point inhibitors**
O. Icht, N. Darzi, Y. Landman, D. Reinhorn, T. Shochatd, O. Jacobi, O. Rotem, E. Dudnik, G. Spectre, P. Raanani, A. Zera, A. Leader
- PO-61 Venous thromboembolic disease in cancer patients treated with immunotherapy: analysis of the TESEO study**
L. Ortega Morán, M. Sánchez Cánovas, J. Pérez Altozano, L. Teijeira Sánchez, J.D. Cumplido Burón, E. Gallardo Díaz, M. Antonio Rebollo, E. Ceballos Barbancho, N. Martínez Lago, M.J. Ortiz Morales, V.E. Castellón Rubio, A. Carmona Bayonas, P. Jiménez Fonseca, E. Martínez de Castro, J. Muñoz Langa, P. Pérez Segura, A.J. Muñoz Martín
- PO-62 Tinzaparin: anti-cancer properties?**
E. Dimakakos, J. Vathiotis, M. Toki, A. Charpidou, K. Pantazopoulos, E. Kotteas, K. Syrigos
- PO-63 Empowering cancer patients for non-pharmacological primary prevention and early recognition of cancer-associated venous thromboembolism (VTE): the EMPATIC-CP survey**
M. Merino, E. Colomé, F. Esposito, C. Beato, A. Araújo, Y. de Miguel, V. Gemas, C. Font
- PO-64 Targeting energetic metabolism as therapeutic approach in cancer**
C. Moreira-Barbosa, A. Decioa, A. Anastasia, L. Brunelli, R. Pastorelli, N. Panini, M. Lupi, M.R. Bani, R. Giavazzi, C. Ghilardi
- PO-65 Pharmaceutical vigilance and education: the first 6 months of a new anticoagulant at a Brazilian cancer institute**
C. Rothschild, A.H. Sabanai, A.A. Santos, C.O. Sousa, R.S. Siqueira, T. Ferretti, A.A.G.S. Brandão, M.P.E. Diz, J. Pereira, V. Rocha
- PO-66 Patient-reported outcome (PRO) assessment of symptom severity and impairment of daily activities in a group of ambulant cancer patients with IPE: correlation with the Hull score**
F. Haque, H. Khan, G. Bozas, G. Avery, J. Palmer, A. Maraveyas
- PO-67 Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired vs outpatient) at diagnosis in the era of incidental events**
M. Aramberri, D. Muñoz-Guglielmetti, D. Pesantez, F. Posch, C. Ay, C. Beato, C. Diaz-Pedroche, C. Font, on behalf of the 4S Project
- PO-68 Analysis of thrombosis and neoplasia pre and postdiagnosis of essential thrombocytemia: implication in survival**
M.V. Cuevas, I. Martínez-Sancho, C. Alonso-Madrigal, G. Hermida, R. Álvarez-Nuño, B. Cuevas
- PO-69 Thrombotic microangiopathy in the differential diagnosis of anemia and thrombocytopenia in patients with pancreatic cancer receiving chemotherapy**
M. García de Herrerros, F. Espósito, T. Saurí, C. Font

13.15 – 13.45

Poster Session 7

Hemostatic system/tumor biology interactions

Chair: M. Camera (Italy)

- PO-70 Anti-tumour miR-7-5p as a novel regulator of TFPI in liver Cancer**
K.B. Skogstrøm, M. Sletten, M. Tinholt, Y. Xing, S. Rayner, N. Iversen
- PO-71 Potential for new trial endpoint: success of functional mammosphere assay in Thrombin Inhibition Preoperatively (TIP) trial in early breast cancer**
J. Castle, J.R. Harvey, R.B. Clarke, C. Holcombe, A. Volleamere, M. Bramley, N.J. Bundred, C.C. Kirwan
- PO-72 Coagulome analyses reveal possible onco-immunological role of coagulation factor V in breast cancer**
M. Tinholt, B. Stavik, X. Tekpli, M. Sletten, Ø. Garred, V. Kristensen, K.K. Sahlberg, P.M. Sandset, N. Iversen
- PO-73 Coagulation-cancer crosstalk: defining the role of von Willebrand factor in breast cancer progression**
S. Patmore, S.P.D. Singh, J. O'Sullivan
- PO-74 Targeting the procoagulant tumour microenvironment in breast cancer**
E.L. Blower, J. Castle, R.B. Clarke, C.C. Kirwan
- PO-75 The relationship between the coagulation and inflammatory phases of wound healing in early breast cancer**
U. Singh, J. Castle, H. Shaker, S. Greenhalgh, U. Hussain, T. Descamps, S. Nash, M. Wilson, R. Hunt, C.C. Kirwan
- PO-76 The T3R domain of thrombospondin-1 delays tumor growth and improves tumor response to chemotherapy by remodeling the tumor vasculature**
D. Pinessi, A. Resovi, L. Morosi, P. Borsotti, A. Berndt, R. Giavazzi, M. Zucchetti, G. Taraboletti
- PO-77 The activity of fibrinogen-like protein 2 (FGL2) is increased in platelets of patients with malignancies**
E. Rabizadeh, R. Guryon, Y. Shahal-Zimra, I. Cherny
- PO-78 Comparison of the inhibitory effect of angiostatin K1-4.5 and new plasminogen fragment K1-5 on generation of plasmin from plasminogen and angiogenesis**
R.B. Aisina, L.I. Mukhametova, K. Gershkovich

PO-79 Red blood cells and hemostasis in cancer

I.A. Tikhomirova, N.V. Kislov, Yu.V. Malysheva, V.A. Lemehova

PO-80 Tissue factor and tissue factor in combination with alpha-1 antitrypsin or REG4 associate with venous thromboembolism in patients with colorectal cancer

R. Van Beijnum, B. Ünlü, R.J. Anijs, E.H. Laghmani, C. Minderhoud, P.J.K. Kuppen, S.C. Cannegieter, H.H. Versteeg, J.T. Buijs

Monday April 26th

11.00 – 11.30

Poster Session 8

Thrombotic risk assessment

Chair: A.J. Ten Cate (The Netherlands)

PO-81 Predicting symptomatic venous thromboembolic events in hospitalised children with cancer: prospective validation of a risk assessment model

G. Del Borrello, P. Peluso, I. Bini, E. Barisone, F. Fagioli, P. Saracco

PO-82 Impede VTE vs saved scores to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma with immunomodulatory drugs: how to choose?

A. Teste, H. Thollot, F. Tinquaut, S. Sotton, B. Tardy, P. Moreau, J.P. Femand, C. Hulin, I. Elalamy, X. Leleu, D. Guyotat, E. Chalayer

PO-83 Assessment model for thrombotic risk in a prospective cohort of newly diagnosed metastatic cancer outpatient candidates for chemotherapy

C. Verzeroli, M. Marchetti, C. Giaccherini, L. Russo, G. Masci, L. Celio, R. Sarmiento, S. Gamba, C.J. Tartari, E. Diani, A. Vignoli, N. Schillaci, P. Gomez, P. Malighetti, D. Spinelli, C. Tondini, S. Barni, F. Giuliani, F. Petrelli, A. D'Alessio, G. Gasparini, M. Minelli, F. De Braud, A. Santoro, R. Labianca, A. Falanga, on behalf of the HYPERCAN Investigators

PO-84 Incidence of venous thromboembolism and Khorana score in patients with sarcoma: a retrospective study in a single institution

C. Figaredo Berjano, A. Zumárraga Cuesta, M.A. Sala González, B. López de San Vicente Hernández, M. Nuño Escolástico, E. Galve Calvo, M.P. Martínez del Prado

PO-85 Finding a risk assessment model for thromboembolic events in hospitalized cancer patients: the INDICATE study

F. Nichetti, G. Montelatici, L. Provenzano, A. Franza, L. Porcu, F. de Braud, M. Platani

PO-86 Can we improve the prediction of the rate of complications following pulmonary embolism diagnosis in cancer patients? Prospective validation of the epiphany INDEX: the PERSEO study

M. Sánchez Cánovas, M. Cejuela Solís, E. Coma Salvans, D. Casado Elia, D. Gómez Sánchez, P. Sampedro Domarco, R. Morales Giménez, M. Biosca Gómez de Tejada, D. Fernández Garay, C. Sánchez Cendra, S. Sequero López, V. Arrazubi Arrula, M. Justo de la Peña, M. Orillo Sarmiento, D. Moreno Muñoz, E. Martínez de Castro, A. Bernal Vidal, I. de la Haba Vacas, R. Sanchez Bayona, I. García Escobar, L. Ortega Morán, A.J. Muñoz Martín, M.J. Martínez Ortiz, P. Jiménez Fonseca, A. Carmona Bayonasa

- PO-87 Comparison of different clinical risk assessment models (RAMs) in ambulatory cancer patients receiving chemotherapy from the Oncothromb-02 study**
A.J. Muñoz Martín, M. Ruiz Zamorano, A. Cárdenas Yebra, L. Ortega Morán, A.I. Ferrer Pérez, A.B. Rupérez Blanco, J. Rubio Pérez, J. Martínez-Galán, C. Font-Puig, I. Fernández Pérez, V. Pachón Olmos, E. Martínez de Castro, T. Quintanar Verdúgez, S. López, V. Rubio Castellón, A. Martínez-Pérez, E. Seguí, X. García Escobar, M. Salgado Fernández, E. Salas Pérez-Rasilla, J.M. Soria Fernández
- PO-88 The Khorana, Protecht, and 5-SNP scores for prediction of venous thromboembolism in cancer patients**
N.A. Guman, F.I. Mulder, N. van Es, L.V. Beerepoot, H. van Laarhoven, M. Lolkema, H.R. Büller
- PO-89 Performance of the '4S rule' to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism**
C. Font, F. Posch, C. Ay, M. Aramberri, D. Pesantez, D. Muñoz-Guglielmetti, C. Beato, C. Diaz-Pedroche, on behalf of the 4S Project
- PO-90 Characterization of thrombosis risk in patients with cancer: preliminary results**
J. Trujillo-Santos, M. Salgado, I. García Escobar, A. Araújo, R. Molina, E. Horvath, R. Porta, J.C. Benítez-Montañez, C. Font-Puig, A.C. Albuquerque, M.J. Ribeiro, D. Hervás, M. Merino, Y. de Miguel, E. Colomé, P. Cerezuela, M. Lobo de Mena, M. Malheiro, for the CARTAGO Study Group on Cancer Associated Thrombosis
- PO-91 Implementing an automated electronic VTE assessment tool for ambulatory oncology patients: a Canadian community cancer centre experience**
L.J. Rotz, B.J.N. Leonard
- PO-92 Evaluation of gemcitabine and platinum agents for the prediction of venous thromboembolism in patients with cancer: results from the Vienna cancer and thrombosis study**
F. Moik, N. van Es, F. Posch, M. Di Nisio, T. Füreder, M. Preusser, I. Pabinger, C. Ay

11.45 – 12.15

Poster Session 9

Bleeding complications

Chair: E. De Candia (Italy)

- PO-93 Anticoagulants related GI bleeding using the EMA pharmacovigilance database**
I. Elalamy, N. Janus
- PO-94 Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases**
A. Leader, E.N. Hamulyák, B.J. Carney, M. Avrahami, J.J. Knip, S. Rozenblatt, L.F.M. Beenen, S. Yust-Katz, M. Coppens, P. Raanani, S. Middeldorp, H.R. Büller, J.I. Zwicker, G. Spectre
- PO-95 Adverse events of rivaroxaban usage in younger versus older cancer patients**
C.P. Escalante, A. Zalpour, J. Song, M. Richardson, J. Halm, S.W. Yusuf, T. Rice, S. Gao
- PO-96 Pediatric cancer patients receiving therapeutic anticoagulation for VTE have a low bleeding risk, but a high risk of recurrence**
S. Lenahan, A. Blackmore, J.S. Palumbo, C. Tarango
- PO-97 Overall survival with warfarin versus low-molecular-weight heparin in cancer-associated thrombosis**
R. Patell, T. Chiasakul, R. Redd, A.M. Khan, E.P. McCarthy, D. Neuberg, J.I. Zwicker
- PO-98 The occurrence of thrombocytopeny in CLL patients treated with ibrutinib**
K. Chasakova, L. Slavík, D. Starostka, J. Úlehlová, T. Papajík, P. Turcsanyi, R. Urbanová
- PO-99 Non-traumatic subdural hematoma and occult cancer: a Danish nationwide cohort study**
S.H. Okholm, D. Nagy, D.K. Farkas, C.H. Fuglsang, F.S. Troelsen, V.W. Henderson, H.T. Sørensen
- PO-100 Safety of direct oral anticoagulants and vitamin k antagonists in patients with atrial fibrillation and gastrointestinal or urological cancer**
A.G. Ording, M. Søgaard, F. Skjøth, E.L. Grove, T.B. Larsen, P.B. Nielsen
- PO-101 Management of direct oral anticoagulant (DOAC)-related bleeding with andexanet alpha or idarucizumab versus prothrombin complex concentrate (PCC) in patients with cancer: the MD Anderson experience**
J.A. Ross, S. Lee, A. Zalpour, J.T. Henry, C.M. Rojas Hernandez
- PO-102 Bleeding management challenges in rare cancer-associated thrombosis: a case report of inferior vena cava thrombus in a patient with testicular germ cell tumour**
J. Gramaça, D.D. Machado, T. Ponte, I. Pina

12.30 – 13.00

Poster Session 10

New experimental and clinical approaches

Chair: E. Castoldi (The Netherlands)

PO-103 Unravelling the mouse endothelial transcriptome in organs distant from the primary tumor

M. Herre, J. Cedervall, R. Lugano, A. Dimberg, A.K. Olsson

PO-104 Microparticles signature in pancreatic cancer: the BACAP project

D. Mege, M. Aubert, L. Crescence, S. Robert, F. Muscari, B. Bournet, G. Piessen, S. Truant, F. Dignat-George, L. Panicot-Dubois, C. Dubois

PO-105 Quantification of citrullinated histones in human blood samples: challenges and development of a nucleosome-based assay to quantify H3Cit-DNA in human plasma

C. Thålin, K. Aguilera, N.W. Hall, M.R. Marunde, J.M. Burg, A. Rosell, M. Daleskog, Y. Hisada, M.J. Meiners, Z.W. Sun, M.F. Whelihan, M.A. Cheek, S.A. Howard, S. Saxena-Beem, D.F. Noubouossie, N.S. Key, S.Z. Sheikh, M.C. Keogh, M.W. Cowles, S. Lundström, N. Mackman, H. Wallén, A.L. Johnstone

PO-106 Effect of single dose prophylactic bemiparin on the levels of citrullinated histone in cancer hospitalized patient

R. Figueroa, M. Marcos-Jubilar, A. García-Mouriz, J.A. Páramo, R. Lecumberri

PO-107 Neutrophil extracellular traps promote cancer-associated heart dysfunction

J. Cedervall, M. Herre, C. Thålin, H. Wallén, V. Hjalmar, E. Hagström, A. Larsson, A.K. Olsson

PO-108 Antiangiogenic effects of acetylsalicylic acid in patients with polycythemia vera

A. Shabalina, M. Tanashyan, E. Roitman, P. Kuznetsova, Z. Khamidova

PO-109 D-dimer, P-selectin and microparticles as biomarkers of occult cancer in unprovoked venous thromboembolism (VTE) patients

S. Marín-Romero, V. Sánchez López, A. Dorado Elias, E. Arellano Orden, T. Elias Hernández, L. Jara-Palomares, M.I. Asensio Cruz, F.J. Rodriguez Martorell, J.L. Lobo Beristaín, R. Otero Candelera

PO-110 Identification of novel biomarkers to aid in the detection of occult cancer in high-risk patient populations: the BIT and MEDECA studies

C. Thålin, A. Rosell, L. Gabrielsson, M. Månsson, K. Aguilera, S. Lundström, M. Söderberg, V. Hjalmar, H. Wallén, for the BIT and MEDECA Study Group

PO-111 Blood group B is a potent risk factor for venous thromboembolism in glioblastoma multiforme

K.M. Heenkenda, A. Malmström, M. Lysiak, M. Mudaisi, C. Bratthäll, P. Milos, M. Strandeus, L. Åkesson, P. Söderkvist, S. Uppugunduri, A.M. Osman

PO-112 Forthcoming study of a novel assay for the stratification of cancer patients' risk of thromboembolism

I. Tzoran, T. Katz, J. Romano, B. Brenner

PO-113 Platelet function in polycythemia vera and primary myelofibrosis using multiple electrode aggregometry

N.S. Nytofte, O.B. Pedersen, H.C. Hasselbalch

A

Abu Saadeh, F. PO-03
 Agnelli, G. PL-24
 Aguilera, K. PO-28, PO-105, PO-110
 Ahmed, A. PO-52
 Aisina, R.B. PO-78
 Åkesson, L. PO-111
 Albuquerque, A.C. PO-90
 Albuquerque, G.M. PO-40
 Ali, N.A. PO-52
 Alonso-Madrigal, C. PO-68
 Álvarez-Nuño, R. PO-68
 Anagnostopoulos, N. PO-50
 Anastasia, A. PO-64
 Anijs, R.J.S. PO-13, PO-80
 Antonio Rebollo, M. PO-61
 Aramberri, M. PO-51, PO-67, PO-89
 Araújo, A. PO-63, PO-90
 Arellano Orden, E. OC-08, PO-109
 Arif, A. PO-36
 Arrazubi Arrula, V. PO-86
 Asencio Cruz, M.I. OC-08, PO-109
 Aubert, M. PO-104
 Avery, G. PO-66
 Avrahami, M. PO-94
 Ay, C. OC-11, OC-13, PO-67, PO-89, PO-92
 Azevedo, D. PO-08, PO-09

B

Baddeley, E. PO-04, PO-48
 Balabanova, Y. PO-20, PO-45
 Balkanov, A.S. PO-32
 Bani, M.R. PO-64
 Barbosa, M. PO-08, PO-09
 Barišić, B. PO-57
 Barisone, E. PO-81
 Barni, S. PO-83
 Baroni, M. PO-25
 Basdeki, K. PO-17
 Battiston, S.L. PO-42
 Batuyong, E. PO-55
 Beato, C. PO-63, PO-67, PO-89
 Beenen, L.F.M. PO-94
 Beerepoot, L.V. PO-88
 Benegas, M. PO-51
 Benítez-Montañez, J.C. PO-90
 Bernal Vidal, A. PO-86
 Bernardi, F. PO-25
 Berndt, A. PO-76
 Bertoletti, L. OC-15, OC-17, PO-39, PO-46

Bini, I. PO-81
 Biosca Gómez de Tejada, M. PO-86
 Bischoff, S. PO-37
 Bitsadze, V.O. PO-31, PO-59
 Blackmore, A. PO-96
 Blanco Abad, C. OC-02, PO-21, PO-56, PO-58
 Blasco-Esquivias, I. OC-08
 Blower, E.L. PO-74
 Borsotti, P. PO-76
 Bosch, F.T.M. OC-14
 Bournet, B. OC-04, PO-104
 Bozas, G. PO-66
 Brækkan, S.K. PO-13
 Bramley, M. PO-71
 Brandão, A.A.G.S. PO-40, PO-65
 Bratthäll, C. PO-111
 Brekke, J. OC-16
 Brenner, B. PL-05, PO-112
 Brobert, G. PO-20, PO-45
 Brodmann, M. PO-34, PO-41
 Brøndum Frøkjær, J. PO-23
 Brunelli, L. PO-64
 Buijs, J.T. PO-80
 Bulato, C. PO-29
 Büller, H.R. OC-05, OC-14, PO-88, PO-94
 Bundred, N.J. PO-71
 Bura-Rivière, A. OC-15
 Burg, J.M. PO-105
 Buscail, L. OC-04

C

Cadavez, E. PO-08, PO-09
 Calzas, J. OC-13
 Campagnaro, T. PO-25
 Campello, E. PO-29, PO-30
 Canivet, C. OC-04
 Cannegieter, S.C. PL-03, PO-13, PO-80
 Cantrell, R. OC-10
 Cárdenas Yebra, A. PO-87
 Carmona Bayonas, A. PO-61, PO-86
 Carney, B.J. PO-94
 Carrier, M. OC-14, PO-02
 Casado Elia, D. PO-86
 Castagna, A. PO-25
 Castellón Rubio, V.E. OC-13, PO-61
 Castelo Branco, M. PO-08, PO-09
 Castle, J. PO-71, PO-74, PO-75
 Catella-Chatron, J. PO-46

Catoya Villa, J.L. OC-02, PO-21, PO-56, PO-58
 Ceballos Barbancho, E. PO-61
 Cedervall, J. PO-103, PO-107
 Cejuela Solís, M. PO-86
 Celio, L. PO-83
 Cerezuela, P. PO-90
 Chalayer, E. PO-82
 Chalchal, H. PO-43
 Chan, E.R. OC-06
 Chapman, O. PO-36
 Charpidou, A. PO-62
 Chasakova, K. PO-98
 Cheek, M.A. PO-105
 Cherny, I. PO-77
 Chiasakul, T. PO-97
 Cholidou, K. PO-50
 Christensen, T.D. PO-38
 Christiansen, C.F. PO-15
 Christiansen, O.B. PO-11
 Christos, P. PO-33
 Clarke, R.B. PO-71, PO-74
 Colomé, E. PO-63, PO-90
 Coma Salvans, E. PO-86
 Conci, S. PO-25
 Connors, J.M. L-01, OC-04, OC-14
 Cooley, B.C. OC-11
 Coppens, M. PO-94
 Costanzo, S. OC-03, PO-26, PO-27
 Cowles, M.W. PO-105
 Crabtree, A. PO-04, PO-48
 Crescence, L. PO-104
 Crobach, M.J.T. PO-13
 Cuevas, B. PO-68
 Cuevas, M.V. PO-68
 Cumplido Burón, J.D. PO-61

D

D'Alessio, A. PO-83
 D'Sa, S. PO-05
 Da Costa, A. PO-46
 Dahm, A.E.A. OC-16
 Daleskog, M. PO-28, PO-105
 Damaraju, C.V. OC-12
 Darzi, N. PO-60
 De Braud, F. PO-83, PO-85
 De Curtis, A. PO-26, PO-27
 de Gaetano, G. OC-03, PO-26, PO-27
 De la Cruz, S. OC-01
 de la Haba Vacas, I. PO-86
 de Miguel, Y. PO-63, PO-90

de Wit, M. PO-37
 Decioa, A. PO-64
 Del Borrello, G. PO-81
 Descamps, T. PO-75
 Di Castelnuovo, A. OC-03, PO-26, PO-27
 Di Nisio, M. OC-14, PO-92
 Diani, E. PO-83
 Diaz-Pedroche, C. PO-51, PO-67, PO-89
 Dignat-George, F. PO-104
 Dimakakos, E. PO-16, PO-17, PO-24, PO-50, PO-62
 Dimberg, A. PO-103
 Diz, M.P.E. PO-40, PO-65
 Donati, M.B. OC-03, PO-26, PO-27
 Dorado Elias, A. PO-109
 Doulioglou, V. PO-49
 Duarte, S. PO-08, PO-09
 Dubois, C. PL-17, PO-104
 Dudnik, E. PO-60
 Dunn, J.A. PO-36

E

Easaw, J. PO-55
 Elalamy, I. PO-82, PO-93
 Elias Hernández, T. OC-08, PO-109
 Enden, T. OC-16
 Erichsen, R. PO-19, PO-47, PO-54
 Erlich, J. OC-11
 Escalante, C.P. PO-95
 Esposito, F. PO-51, PO-63, PO-69

F

Fadin, M. PO-29
 Fagioli, F. PO-81
 Falanga, A. PO-26, PO-27, PO-83
 Faletar, J. PO-57
 Farahmand, B. PO-20, PO-45
 Farge, D. OC-04
 Farkas, D.K. PO-12, PO-14, PO-15, PO-18, PO-53, PO-99
 Femand, J.P. PO-82
 Fernández Garay, D. PO-86
 Fernández Pérez, I. PO-87
 Ferrer Pérez, A.I. PO-87
 Ferretti, T. PO-65
 Figaredo Berjano, C. PO-84
 Figueroa, R. OC-07, PO-106
 Fisker, R.V. PO-23
 Flick, M.J. OC-11

Font, C. OC-13, PO-51, PO-63, PO-67, PO-69, PO-87, PO-89, PO-90
 Forbes, G.L. OC-06
 Fouilloux, A. PO-46
 Fraise, J. OC-04
 Franza, A. PO-85
 Frappé, P. PO-39
 French, K. PO-36
 Frere, C. OC-04
 Friso, S. PO-25
 Frøen, H. OC-16
 Fuglsang, C.H. PO-18, PO-99
 Füreder, T. PO-92

G

Gabrielsson, L. PO-110
 Gade, I.L. PO-10, PO-11
 Gago, P. PO-08, PO-09
 Galić, E. PO-57
 Gallagher, K. PO-07
 Gallardo Díaz, E. PO-61
 Galve Calvo, E. PO-84
 Gamba, S. PO-26, PO-27, PO-83
 Gao, S. PO-95
 García de Herrerros, M. PO-69
 García Escobar, I. PO-86, PO-90
 García Escobar, X. PO-87
 Garcia, D. OC-14
 García-Mouriz, A. OC-07, PO-106
 García-Villa, A. PO-51
 Garmo, H. PO-20, PO-45
 Garratt, K.B. OC-11
 Garred, Ø. PO-72
 Garresori, H. OC-16
 Gary, T. PO-34, PO-41
 Gasparini, G. PO-83
 Gates, C. PO-06
 Gavasso, S. PO-29, PO-30
 Gemas, V. PO-63
 Gerotziafas, G.T. PO-16, PO-24, PO-50
 Gershkovich, K. PO-78
 Ghadessi, M. OC-09
 Ghanima, W. OC-16
 Ghenassia-Fouillet, L. PO-39
 Ghilardi, C. PO-64
 Ghosh, S. PO-55
 Giaccherini, C. PO-83
 Giavazzi, R. PO-64, PO-76
 Girard, P. OC-17
 Giuliani, F. PO-83
 Gkiozos, I. PO-17, PO-24, PO-50

Gleeson, N. PO-03
 Gomes, R. PO-08, PO-09
 Gómez Sánchez, D. PO-86
 Gomez, P. PO-83
 Gourgou, S. OC-04
 Gramaça, J. PO-102
 Greenhalgh, S. PO-75
 Gressenberger, P. PO-34, PO-41
 Grilo, I. PO-08, PO-09
 Grilz, E. OC-13
 Grosso, M. OC-14
 Grove, E.L. PO-100
 Grover, S.P. OC-11
 Guetl, K. PO-41
 Guglielmi, A. PO-25
 Guichard, J.B. PO-46
 Guman, N.A. PO-88
 Guryon, R. PO-77
 Gutiérrez Ortiz de la Tabla, A. OC-02, PO-21, PO-56, PO-58
 Gütl, K. PO-34
 Guyotat, D. PO-82

H

Habel, P. PO-37
 Haddad, P. PO-07
 Hagström, E. PO-107
 Hale, D. PO-36
 Hall, N.W. PO-105
 Halm, J. PO-95
 Hammerstrøm, J. PO-13
 Hammoud, D. PO-07
 Hamulyák, E.N. PO-94
 Hannevik, T.L. OC-16
 Hansen, J. PO-13
 Haque, F. PO-66
 Harvey, J.R. PO-71
 Hasselbalch, H.C. PO-113
 Hatzipantelis, E. PO-49
 Heenkenda, K.M. PO-111
 Heitmeier, S. OC-09
 Henderson, V.W. PO-18, PO-99
 Henry, J.T. PO-101
 Hermida, G. PO-68
 Herre, M. PO-103, PO-107
 Hervás, D. PO-90
 Hill, C. PO-36
 Hisada, Y. OC-11, PO-28, PO-105
 Hjalmar, V. PO-107, PO-110
 Hobbs, E.D.R. PO-36
 Højen, A.A. PO-38
 Holcombe, C. PO-71

Horvath, E. PO-90
 Horváth-Puhó, E. OC-05
 Howard, S.A. PO-105
 Hulin, C. PO-82
 Hunt, R. PO-75
 Hussain, U. PO-75

I

Iacoviello, L. OC-03, PO-26, PO-27
 Icht, O. PO-60
 Ilich, A. PO-02
 Illarramendi, J. OC-01
 Illarramendi, J.J. OC-01
 Ioannidou, M. PO-49
 Iversen, N. PO-70, PO-72

J

Jacobi, O. PO-60
 Jacobsen, E.M. OC-16
 Janssen, E. OC-10
 Janus, N. PO-93
 Jara Palomares, L. PL-01, OC-08, PO-109
 Jiménez Fonseca, P. PO-61, PO-86
 Johnstone, A.L. PO-105
 Jühling, A. PO-37
 Juliao Caamaño, D.S. OC-02, PO-21, PO-56, PO-58
 Justo de la Peña, M. PO-86

K

Kahr, H.S. PO-11
 Kainis, E. PO-16
 Kakkar, A.J. PL-23, PO-36
 Karakatsanis, S. PO-24
 Karametou, M. PO-49
 Kashan, A. PO-03
 Katz, T. PO-112
 Kawano, T. OC-11
 Keddie, S. PO-05
 Kenet, G. PL-04
 Keogh, M.C. PO-105
 Key, N.S. PL-10, PO-02, PO-105
 Khamidova, Z. PO-108
 Khan, A.M. PO-97
 Khan, H. PO-66
 Khizroeva, D.Kh. PO-31, PO-59
 Khmelevskaya, A.N. -32
 Khorana A.A. OC-12
 Kirwan, C.C. PO-71, PO-74, PO-75
 Kislov, N.V. PO-79

Kjaergaard, A.D. PO-15
 Klamroth, R. PO-37
 Knip, J.J. PO-94
 Knudsen, A. PO-11
 Köck, T. OC-09
 Kokkotou, E. PO-24
 Koletsa, T. PO-49
 Konstantinides, S. OC-09
 Körmendiné Farkas, D. PO-19, PO-47, PO-54
 Kotteas, E. PO-16, PO-17, PO-24, PO-50, PO-62
 Kragholmd, K.K. PO-10
 Kristense, S.R. PO-13, PO-10, PO-23
 Kristensen, V. PO-72
 Kuderer, N. PL-21, OC-12
 Kumar, V. PO-02
 Kümler, T. PO-38
 Kuppen, R.J.K. PO-80
 Kuznetsova, P. PO-108

L

Labianca, R. PO-83
 Ladeira, K. PO-08, PO-09
 Laghmani, E.H. PO-80
 Landman, Y. PO-60
 Lapébie, F.X. OC-15
 Laporte, S. OC-17
 Larsen, A.C. PO-23
 Larsen, T.B. PO-38, PO-100
 Larsson, A. PO-107
 Le Hello, C. PO-39
 Leader, A. PL-07, PO-60, PO-94
 Lecumberri, R. OC-07, PO-106
 Lee, S. PO-101
 Lehn, M. OC-10
 Leleu, X. PO-82
 Lemehova, V.A. PO-79
 Lenahan, S. PO-96
 Lenz, M. OC-09
 Leonard, B.J.N. PO-91
 Lerche, V. PO-39
 Levi, M.M. PL-02
 Levine, M. PO-36
 Lindahl, L.M. PO-53
 Liu, P. PO-08, PO-09
 Livanios, K. PO-16
 Liz Pimenta, J. PO-08, PO-09
 Lobo Beristáin, J.L. PO-109
 Lobo de Mena, M. PO-90
 Lokare, A. PO-36

Lolkema, M. PO-88
 López de San Vicente Hernández, B. PO-84
 López Jiménez, C. OC-02, PO-21, PO-56, PO-58
 López, S. OC-13, PO-87
 Lugano, R. PO-103
 Lundström, S. PO-28, PO-105, PO-110
 Lunn, M.P. PO-05
 Lupi, M. PO-64
 Lyman, G.H. OC-12
 Lysiak, M. PO-111

M

Machado, D.D. PO-102
 Mackman, N. OC-11, PO-28, PO-105
 Magné, N. PO-46
 Mahé, I. OC-17
 Makatsariya, A.D. PO-31, PO-59
 Malheiro, M. PO-90
 Malighetti, P. PO-83
 Mallick, R. PO-02
 Malmström, A. PO-111
 Malysheva, Yu.V. PO-79
 Månsson, M. PO-110
 Maqsood, A. OC-11
 Maraveyas, A. PL-20, PO-36, PO-66
 Marchetti, M. PL-11, PO-26, PO-27, PO-83
 Marchocki, Z. PO-03
 Marcos-Jubilar, M. OC-07, PO-106
 Maredza, M. PO-36, PO-44
 Marín Romero, S. OC-08, PO-109
 Marobin, M. PO-30
 Marshall, A. PO-36, PO-44
 Martín Jiménez, M. OC-02, PO-56, PO-58
 Martín, M. PO-21
 Martinelli, N. PO-25
 Martínez de Castro, E. PO-61, PO-86, PO-87
 Martínez del Prado, M.P. PO-84
 Martínez Lago, N. PO-61
 Martínez Ortiz, M.J. PO-86
 Martínez, E. OC-13
 Martínez-Galán, J. PO-87
 Martínez-Marín, V. OC-13
 Martínez-Pérez, A. PO-87
 Martínez-Sancho, I. PO-68
 Marunde, M.R. PO-105
 Masci, G. PO-83

Mateshaytis, J. PO-55
 McCarthy, E.P. PO-97
 McCrae, K. OC-12
 Medina Badenes, P. OC-08
 Medugorac, M. PO-57
 Mege, D. PO-104
 Meiners, M.J. PO-105
 Memon, A.M. PO-52
 Meng, M. PO-31, PO-59
 Merah, A. OC-15
 Merino, M. PO-63, PO-90
 Merkulova, A.A. OC-06
 Mery, B. PO-46
 Metelin, V.B. PO-32
 Meyer, G. OC-17
 Middeldorp, S. PO-94
 Milos, P. PO-111
 Minderhoud, C. PO-80
 Minelli, M. PO-83
 Mismetti, P. OC-17
 Mitchell, S.C. OC-06
 Modesto, J.L. OC-01
 Moik, F. OC-11, PO-92
 Molina, R. PO-90
 Monia, B. OC-10
 Monreal, M. OC-15
 Montelatici, G. PO-85
 Moodley, O.M. PO-43
 Morales Giménez, R. PO-86
 Moreau, P. PO-82
 Moreira-Barbosa, C. PO-64
 Morel, A. PO-39
 Moreno Muñoz, D. PO-86
 Morosi, L. PO-76
 Moruzzi, S. PO-25
 Mosalskaya, D.V. PO-32
 Mpakakos, P. PO-17, PO-50
 Mudaisi, M. PO-111
 Mukhametova, L.I. PO-78
 Mulder, F. OC-05, OC-14, PO-88
 Muñoz Langa, J. PO-61
 Munoz Martin, A.J. PL-22, OC-02, OC-13, PO-21, PO-56, PO-58, PO-61, PO-86, PO-87
 Muñoz-Guglielmetti, D. PO-67, PO-89
 Mureb, D. OC-10
 Muscari, F. PO-104
 Muster, V. PO-34, PO-41

N

Nadir, Y. PL-16

Næssk, I.A. PO-13
 Nagy, D. PO-12, PO-14, PO-15, PO-18, PO-47, PO-53, PO-54, PO-99
 Nanus, D.M. PO-33
 Nash, S. PO-75
 Nauseef, J. PO-33
 Nelson, A. PO-04, PO-48
 Nelson, A.C. OC-17
 Neuberg, D. PO-97
 Nichetti, F. PO-85
 Nielsen, P.B. PO-100
 Noble, S. PL-25, PO-04, PO-48
 Norris, L.A. PO-03
 Noubouossie, D.F. PO-105
 Nuño Escolástico, M. PO-84
 Nybo, M. PO-38
 Nytofte, N.S. PO-113

O

O'Sullivan, J. PO-73
 O'Toole, S.A. PO-03
 Okholm, S.H. PO-99
 Olivieri, O. PO-25
 Olsson, A.K. PO-103, PO-107
 Ording, A.G. PO-100
 Orillo Sarmiento, M. PO-86
 Ortega Morán, L. OC-02, PO-21, PO-56, PO-61, PO-58, PO-86, PO-87
 Ortiz Morales, M.J. PO-61
 Osman, A.M. PO-111
 Otero Candelera, R. OC-08, PO-109
 Oto Martinez, J. OC-08
 Overvad, K. PO-13

P

Pabinger, I. Simon Karpatkin Memorial Lecture, OC-11, OC-13, PO-92
 Pachón, V. OC-13, PO-87
 Palabougiouki, M. PO-49
 Palmer, J. PO-66
 Palumbo, J.S. PL-18, OC-10, PO-96
 Panicot-Dubois, L. PO-104
 Panini, N. PO-64
 Panova-Noeva, M. OC-09
 Pantazopoulos, K. PO-62
 Panzera, T. PO-27, PO-26
 Papageorgiou, T. PO-49
 Papajik, T. PO-98
 Páramo, J.A. OC-07, PO-106
 Parisi, R. OC-03

Pastorelli, R. PO-64
 Patel, J. OC-12
 Patell, R. PO-97
 Patmore, S. PO-73
 Patoulías, I. PO-49
 Pattini, P. PO-25
 Paulsen, B. PO-13
 Paulsen, P.Q. OC-16
 Pavlidou, E. PO-49
 Pavlou, E. PO-49
 Pease, N. PO-04, PO-48
 Pedersen, L. OC-05
 Pedersen, O.B. PO-113
 Peluso, P. PO-81
 Pereira, J. PO-40, PO-65
 Pérez Altozano, J. PO-61
 Pérez Segura, P. PO-61
 Persichillo, M. PO-26, PO-27
 Pesantez, D. PO-67, PO-89
 Petrelli, F. PO-83
 Petrou, S. PO-36, PO-44
 Petrova, O.Y. PO-01
 Petrova, S.S. PO-59
 Piessen, G. PO-104
 Pin, S. PO-55
 Pina, I. PO-102
 Pinessi, D. PO-76
 Platani, M. PO-85
 Pollich, C. PO-37
 Ponte, T. PO-102
 Porcu, L. PO-85
 Porojnicu, A.C. OC-16
 Porta, R. PO-90
 Posch, F. PO-67, PO-89, PO-92
 Prassopoulos, P. PO-49
 Preusser, M. PO-92
 Provenzano, L. PO-85
 Ptohis, N. PO-17

Q

Quintanar Verdúgez, T. PO-87

R

Raanani, P. PO-60, PO-94
 Rabizadeh, E. PO-77
 Radu, C.M. PO-29
 Raggam, R.B. PO-34, PO-41
 Rak, J. PL-14
 Rapp, S. OC-09
 Raskob, G. OC-14
 Rasmussen, M.S. PO-38

Rayner, S. PO-70
 Redd, R. PO-97
 Ree, A.H. OC-16
 Reinhorn, D. PO-60
 Remuzzi, A. SPL
 Resovi, A. PO-76
 Revenko, A. OC-10
 Ribeiro, M.J. PO-90
 Rice, T. PO-95
 Richardson, M. PO-95
 Riddersholm, S.J. PO-10, PO-11
 Riess, H. PO-37
 Robert, S. PO-104
 Rocha, M. PO-08, PO-09
 Rocha, V. PO-40, PO-65
 Rodriguez de la Borbolla, M. OC-08
 Rodriguez Martorell, F.J. OC-08, PO-109
 Rodriguez-Hernandez, A. PO-51
 Roitman, E. PO-108
 Rojas Hernandez, C.M. PO-101
 Romano, J. PO-112
 Romero, M.B. PO-42
 Rosell, A. PO-28, PO-105, PO-110
 Rosenfeldt, L. OC-10
 Rosin, E. PO-29
 Ross, J.A. PO-101
 Rotem, O. PO-60
 Rothschild, C. PO-40, PO-65
 Rotz, L.J. PO-91
 Rovina, N. PO-17
 Rowinski, E. PO-46
 Rozenblatt, S. PO-94
 Rubio Castellón, V. PO-87
 Rubio Pérez, J. PO-87
 Ruf, W. PL-15
 Ruiz Zamorano, M. PO-87
 Rupérez Blanco, A.B. PO-87
 Rupérez, A. OC-13
 Russo, L. PO-26, PO-27, PO-83
 Ruzzenente, A. PO-25

S

Sabanai, A.H. PO-40, PO-65
 Sahlberg, K.K. PO-72
 Sala González, M.A. PO-84
 Salas Pérez-Rasilla, E. PO-87
 Salas, E. OC-13
 Salgado Fernández, M. PO-87
 Salgado, E. OC-01
 Salgado, M. OC-13, PO-90

Sampedro Domarco, P. PO-86
 Sanchez Bayona, R. PO-86
 Sánchez Cánovas, M. PO-61, PO-86
 Sánchez Cendra, C. PO-86
 Sánchez Díaz, J.M. OC-08
 Sánchez López, V. OC-08, PO-109
 Sanchez, M. PO-51
 Sanchez, O. OC-17
 Sandset, P.M. OC-16, PO-72
 Sanfilippo, K. PL-08
 Sannikova, V.S. PO-59
 Santoro, A. PO-83
 Santos, A.A. PO-65
 Sanz, M.A. PL-06
 Saracco, P. PO-81
 Sarmiento, T. PO-08, PO-09
 Sarmiento, R. PO-83
 Saurí, T. PO-69
 Saxena-Beem, S. PO-105
 Sayar, Z. PO-05, PO-06
 Schillaci, N. PO-83
 Schmaier, A.H. OC-06
 Scholz, C.W. PO-37
 Schönfeldt Troelsen, F. PO-19, PO-47, PO-54
 Schulz, A. OC-09
 Schweiger, L. PO-34
 Segers, A. OC-14
 Seguí, E. PO-51, PO-87
 Selby, R. PL-09
 Sequero López, S. PO-86
 Severinsen, M.T. PO-10, PO-13
 Sevestre, M.-A. PO-39
 Sfougaris, D. PO-49
 Shabalina, A. PO-108
 Shahal-Zimra, Y. PO-77
 Shaker, H. PO-75
 Sharma, B.K. OC-10
 Shaw, J. PO-02
 Sheikh, S.Z. PO-105
 Shochatd, T. PO-60
 Shorova, M. PO-22, PO-35
 Simion, C. O-30, PO-29
 Simioni, P. PO-29, PO-30
 Singh, S.P.D. PO-73
 Singh, U. PO-75
 Sinn, M. PO-37
 Siqueira, R.S. PO-65
 Sive, J. PO-05
 Skajaa, N. PO-12, PO-47, PO-54
 Skille, H. PO-13
 Skjøth, E. PO-100

Skogstrøm, K.B. PO-70
 Slavík, L. PO-98
 Sletten, M. PO-70, PO-72
 Smadja, D.M. L-02
 Söderberg, M. PO-110
 Söderkvist, P. PO-111
 Søgaaard, M. PO-100
 Solier-López, A. OC-08
 Solopova, A.G. PO-31, PO-59
 Song, J. PO-95
 Sørensen, H.T. OC-05, PO-12, PO-14, PO-15, PO-18, PO-19, PO-47, PO-54, PO-99
 Sørensen, S.T. PO-53
 Soria Fernández, J.M. OC-13, PO-87
 Sotton, S. PO-82
 Sousa, C.O. PO-65
 Sousa, M. PO-08, PO-09
 Spaeth-Schwalbe, E. PO-37
 Spectre, G. PO-60, PO-94
 Spiezia, L. PO-29
 Spinelli, D. PO-83
 Starostka, D. PO-98
 Stattin, P. PO-20, PO-45
 Stavik, B. PO-72
 Stavrou, E.X. OC-06
 Stefanou, D. PO-16
 Strandeus, M. PO-111
 Sukhanov, V.A. PO-01
 Sulma, J. PO-04
 Sulman, J. PO-48
 Sun, M. PO-33
 Sun, Z.W. PO-105
 Svingel, L.S. PO-14
 Syrigos, K. PO-16, PO-17, PO-24, PO-62
 Syrigos, N. PO-50

T

Tagawa, S.T. PO-33
 Takahashi, T.T. PO-40
 Tanashyan, M. PO-108
 Taraboletti, G. PO-76
 Tarango, C. PO-96
 Tardy, B. PO-82
 Tartari, C.J. PO-83
 Teijeira Sánchez, L. PO-61
 Teira, A. PO-08, PO-09
 Tekpli, X. PO-72
 ten Cate, H. OC-09
 ten Cate, V. OC-09

Teste, A. PO-82
 Thålin, C. PO-28, PO-105, PO-107, PO-110
 Thirlwall, J. PO-36
 Thollot, H. PO-82
 Thomas, C. PO-33
 Thomas, M. PO-05, PO-06
 Thorlacius-Ussing, O. PO-11, PO-23
 Tikhomirova, I.A. PO-79
 Tinholt, M. PO-70, PO-72
 Tinquaut, F. PO-46, PO-82
 Tjønneland, A. PO-13
 Toki, M. PO-62
 Tondini, C. PO-83
 Torfoss, D. OC-16
 Tormene, D. PO-30
 Torp-Pedersen, C. PO-10, PO-11
 Tragiannidis, A. PO-49
 Troelsen, F.S. PO-53, PO-12, PO-14, PO-15, PO-18, PO-99
 Trontzas, I. PO-17
 Truant, S. PO-104
 Trujillo-Santos, J. PO-90
 Tsagakouli, S. PO-17
 Tso, M.T. PO-43
 Turatti, G. PO-30
 Turcsanyi, P. PO-98
 Tzoran, I. PO-112

U

Udali, S. PO-25
 Úlehlová, J. PO-98
 Ünlü, B. PO-80
 Uppugunduri, S. PO-111
 Urbanová, R. PO-98

V

Vadhan-Raj, S. OC-12
 Van Beijnum, R. PO-80
 Van Dreden, P. PO-25
 van Es, N. OC-05, OC-14, PO-88, PO-92
 van Laarhoven, H.W.M. OC-05, PO-88
 Vasilenko, I.A. PO-32
 Vassias, A. PO-16
 Vassos, D. PO-24
 Vathiotis, J. PO-62
 Velle, E.O. OC-16
 Verhamme, P. OC-14

Versteeg, H.H. PL-12, PO-13, PO-80
 Verzeroli, C. PO-83
 Vignoli, A. PO-83
 Vijapurkar, U. OC-12
 Vilaseca, A.B. PO-42
 Volleamere, A. PO-71
 Vorobyev, A.V. PO-31, PO-59

W

Wagner, B. OC-09
 Wallén, H. PO-28, PO-105, PO-107, PO-110
 Wang, T.F. OC-14
 Weatherill, A. PO-05
 Weitz, J. OC-14
 Wells, P. PO-02
 Whelihan, M.F. PO-105
 Wik, H.S. OC-16
 Wild, P. OC-09
 Wildgoose, P. OC-12
 Wilkie, V. PO-36
 Wilson, M. PO-75
 Wislocka, L. PO-37
 Wolter, E. PO-37
 Woodhams, B. PO-25
 Wun, T. OC-12

X

Xing, Y. PO-70

Y

Yilmaz, M. PO-23
 Young, A.M. PO-36, PO-44
 Yust-Katz, S. PO-94
 Yusuf, S.W. PO-95

Z

Zakharia, Y. PO-33
 Zalpou, A. PO-95, PO-101
 Zeerleder, S. PL-13
 Zeng, P. OC-06
 Zera, A. PO-60
 Zerati, A.E. PO-40
 Zhou, X. OC-12
 Zink, A. OC-09
 Zucchetti, M. PO-76
 Zumárraga Cuesta, A. PO-84
 Zupančić-Šalek, S. PO-57
 Županić Krmek, D. PO-57
 Zwicker, J.I. PL-19, PO-94, PO-97



LEO Pharma

April 22nd, 2021

from 17.15 to 18.15

📍 Room 5

Balancing the Yin and Yang between oncology and thrombosis - A 360° approach to CAT management

Chairs: A.Y.Y. Lee (Canada), W. Ageno (Italy)

Introduction and Welcome

A.Y.Y. Lee (Canada) and W. Ageno (Italy)

Making therapeutic choices in CAT – reviewing evidence from the VTE experts' perspective

A.Y.Y. Lee (Canada)

Can we better link the oncology and thrombosis challenges when managing cancer patients? The Medical Oncologist perspective

J.-P. Spano (France)

Can we bring cancer patients to the centre of our decision making? The Multi-Disciplinary Team approach to ensure informed decisions

P. Leonard (UK)

Questions & Answers facilitation

W. Ageno (Italy)



Sanofi

April 24th, 2021

from 14.00 to 15.00

📍 Room 5

Optimizing Venous ThromboEmbolism management in Cancer patients: from latest evidence to clinical choices

Chair: A. Falanga (Italy)

Introduction and Welcome

A. Falanga (Italy)

VTE prevention in cancer surgery: a state of the art view

J. Arcelus (Spain)

VTE prevention in medical cancer patients: optimizing diagnosis and management

M. Carrier (Canada)

Treatment of VTE in cancer-associated thrombosis: where do we stand?

A. Munoz (Spain)

Q&A session

All

Conclusion & Take home messages

A. Falanga (Italy)



Bayer

April 26th, 2021

from 17.15 to 18.15

📍 Room 5

Addressing controversies in cancer associated thrombosis

Chair: A.J. Kakkar (UK)

CAT: Do we need to change current paradigms?

A.J. Kakkar (UK)

Controversies in patient risk assessment: implications for acute treatment

A.A. Khorana (USA)

Controversies in the selection and duration of treatment

J. Weitz (Canada)

Controversies in practice: an interactive case discussion

M.Thomas (UK)

Panel and Audience Q&A - Close Panel

VIRTUAL PLATFORM

www.live.ichtic.com

After the registration deadline, registered participants will receive an e-mail in order to enter the virtual platform of the event.

Organizing Secretariat

Servizi C.E.C. Srl
Via Verdi 18 - 24121 Bergamo - Italy
e-mail: info@ichtic.com

For technical assistance

Phone: +39 035 219927

Continuing Medical Education (CME)



The European Accreditation Council for CME (EACCME) and Accreditation Council of Oncology in Europe (ACOE)

The 10th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC), Bergamo, Italy, 23/04/2021-26/04/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 10 European CME credits (ECMEC@s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.



European Board for Accreditation in Hematology (EBAH)

The 10th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) has been reviewed and approved for CME-CPD accreditation by the European Board for Accreditation in Hematology (EBAH). The EBAH has approved this educational activity for a maximum number of 10,5 CME-CPD

credits. Each participant should only collect credits for time that she/he actually spent in the educational activity.

Certificates of Attendance

The organizing secretariat will deliver certificates of attendance to participants by e-mail, after the end of the event.

Oral Communications

Presentation & Discussion

Time at disposal for each Oral Communication is 5 minutes for presentation. At the end of each session, after all the oral communication presentations, there will be a Q&A session. The discussion will be handled by the chairs of the session, using the chat function of the platform.

Posters

Viewing Time

During the days of the event, participants can view posters and listen to pre-recorded poster presentations in the Poster Area of the virtual platform all day long.

Mandatory attendance

During the virtual discussion poster sessions (please see the program pages 20-35).

Discussion

There will be 10 Virtual Poster Discussion Sessions each guided by a chair (duration: 30 minutes each), held in the Room 5 of the virtual platform, as reported in the program (pages 20-35).

Poster authors must be present at the start and during the entire Virtual Poster Session.

The discussion will be handled by the chair using the chat function of the virtual platform. Each presenter will have 2 minutes for the Q&A/discussion of his/her poster with the chairman and participants.

Slide presentation

Speakers and Oral Communications presenters must send their presentation in PowerPoint/Keynote (please specify if containing video/audio) to the Organizing Secretariat (info@ichtic.com) at least within 10.00 CEST of the same day of the respective session.

All presenters must present their slides using the share screen function of the virtual platform. Presentation must be a Microsoft PowerPoint/Keynote file and PC/MAC compatible. Please avoid too much heavy presentations.

Time

The times indicated in the program refer to the Central European Summer Time (CEST) time zone.

Language

The official language of the Conference is English. Translations are not provided.

Exhibition booths

The Exhibition booths are located at the Major Cloister. The exhibition opening times are the same of the Conference.

Follow us



SPONSOR

Platinum



Gold



Silver



Bronze



icthic.com